Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Solid Biosciences Inc. - Common Stock (NQ:SLDB)

4.530 -0.010 (-0.22%)
Streaming Delayed Price Updated: 10:04 AM EDT, Jun 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Solid Biosciences Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation
FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns. 
Via Benzinga
Exposures Product Safety
Can Solid Biosciences Challenge Sarepta in the DMD Market?
Solid Biosciences' Duchenne muscular dystrophy (DMD) drug could provide superior outcomes compared to an already approved medication projected to make billions. 
Via MarketBeat
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors
Appointments Include Industry Veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors 
From Climb Bio, Inc.
Via GlobeNewswire
Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week
Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments. 
Via Stocktwits
Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here?
Solid Biosciences just saw a 32% move to the upside after its trial results impressed. What's next for this firm that analysts still see massive potential in? 
Via MarketBeat
Exposures Product Safety
Solid Biosciences' Retail Following Swells Amid Stock's Best Run In A Year — What's Behind The Move?
Early-stage data from the company's gene therapy candidate SGT-003 for Duchenne muscular dystrophy (DMD) showed encouraging results. 
Via Stocktwits
Solid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data
Solid Biosciences' SGT-003 gene therapy showed strong dystrophin expression, muscle health improvements, and no serious safety concerns in early trial data. 
Via Benzinga
Stocks Quiet As S&P 500 Nears All-Time High
All three major indexes are fresh off weekly wins. 
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
Tuesday's session: gap up and gap down stocks
In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
Wondering what's happening in today's pre-market session?
The US market session of Tuesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why BP Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development
Solid Biosciences advances gene therapies for muscular and cardiac diseases, gaining FDA clearance for SGT-212 and targeting key 2025 milestones. 
Via Benzinga
Exposures Product Safety
Why Cal-Maine Foods Shares Are Trading Higher By 4%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst
Wedbush initiates Solid Biosciences with an Outperform rating, citing the potential of SGT-003 for Duchenne muscular dystrophy and a robust cash runway. 
Via Benzinga
iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
SLDB Stock Earnings: Solid Biosciences Beats EPS for Q2 2024
SLDB stock results show that Solid Biosciences beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
This Planet Fitness Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Via Benzinga
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning! 
Via InvestorPlace
Sarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy
The agency signed off on Elevidys for a broad population of children with the muscle-wasting disease. 
Via Investor's Business Daily
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Sarepta is now just awaiting the FDA's decision on whether to fully approve its gene therapy, and for whom. 
Via Investor's Business Daily
Exposures Product Safety
3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off
With the innovation space possibly getting overstretched, these biotech stocks to buy could benefit from a sector rotation. 
Via InvestorPlace
SLDB Stock Earnings: Solid Biosciences Meets EPS for Q1 2024
SLDB stock results show that Solid Biosciences met analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback
The company could follow Sarepta Therapeutics with a gene therapy for Duchenne muscular dystrophy. 
Via Investor's Business Daily
Blend Labs Reports Q4 Results, Joins Alta Equipment, Despegar.com And Other Big Stocks Moving Higher On Friday
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Friday. Shares of Blend Labs, Inc. (NASDAQ: BLND) rose sharply during Friday’s session after the company reported... 
Via Benzinga
Topics Stocks
Exposures US Equities
5 Value Stocks In The Healthcare Sector
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.